会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明专利
    • Transdermal administration device for bisoprolol
    • 双酚A的超导管理装置
    • JP2008247899A
    • 2008-10-16
    • JP2008057691
    • 2008-03-07
    • Nitto Denko CorpToa Eiyo Ltdトーアエイヨー株式会社日東電工株式会社
    • OKADA KATSUHIROMINAMI KUNIHIROIWAO YOSHIHIROYUASA SHUICHIROMATSUOKA KENSUKE
    • A61K31/138A61K9/70A61P9/06A61P9/10A61P9/12A61P43/00
    • A61K31/138A61K9/7053A61K9/7061
    • PROBLEM TO BE SOLVED: To provide a transdermal administration device which shows a relieved skin irritation at the application, particularly at the peeling, and enables the continuous administration of a therapeutically or preventively effective amount of bisoprolol to a living body. SOLUTION: The transdermal administration device 10 for bisoprolol is equipped with a supporting medium 1 and a pressure-sensitive adhesive layer 2 which is layered on one surface of the supporting medium 1 and contains bisoprolol in the pressure-sensitive adhesive layer 2. The maximum speed of releasing bisoprolol within 24 hours immediately after the application to the skin is not higher than 30 μg/cm 2 /hour, and the speed of releasing bisoprolol at the point 24 hours after the application to the skin is not higher than 10 μg/cm 2 /hour. Thus, not only the skin irritation by bisoprolol is restrained, but also the possibility of side effects such as bradycardia or dizziness by excessive antihypertension are excluded, ensuring sufficient safety. COPYRIGHT: (C)2009,JPO&INPIT
    • 待解决的问题:提供一种透皮给药装置,其在使用时特别是在剥离时显示缓解的皮肤刺激,并且能够将生物体上治疗或预防有效量的比索洛尔连续给药。

      解决方案:比索洛尔的透皮给药装置10配备有支撑介质1和压敏粘合剂层2,其在层压在支撑介质1的一个表面上并在压敏粘合剂层2中含有比索洛尔。 施用于皮肤后24小时内释放比索洛尔的最大速度不高于30μg/ cm 2 / SP /小时,施用后24小时释放比索洛尔的速度 皮肤不高于10μg/ cm 2 / SP /小时。 因此,不仅抑制了比索洛尔的皮肤刺激,而且排除了通过过度抗高血压引起的心动过缓或眩晕等副作用的可能性,确保了足够的安全性。 版权所有(C)2009,JPO&INPIT

    • 2. 发明专利
    • Percutaneous administration device of bisoprolol
    • 双氯酚的经皮给药装置
    • JP2013199486A
    • 2013-10-03
    • JP2013119229
    • 2013-06-05
    • Nitto Denko Corp日東電工株式会社Toa Eiyo Ltdトーアエイヨー株式会社
    • IWAO YOSHIHIROMATSUOKA KENSUKEOKADA KATSUHIROMINAMI KUNIHIROYUASA SHUICHIRO
    • A61K31/138A61K9/70A61K47/32A61K47/34A61P9/06A61P9/10A61P9/12
    • A61K31/138A61K9/7053A61K9/7061
    • PROBLEM TO BE SOLVED: To provide a percutaneous administration device reduced in skin stimulation when applied, in particular, when reapplied, and capable of administrating an amount of bisoprolol effective to therapy or prophylaxis continuously to a living organism.SOLUTION: A percutaneous administration device 10 for bisoprolol includes a support body 1 and a pressure-sensitive adhesive layer 2 laminated on one surface of the support body 1, and the bisoprolol is contained in the pressure-sensitive adhesive layer 2, the maximum value of bisoprolol releasing speed is 30 μg/cm/hour or less in the period from the time just after applied onto a skin up to the lapse of 24 hours, and the bisoprolol releasing speed is 10 μg/cm/hour or less in the period from the time just after applied onto the skin up to the lapse of 24 hours. The skin is thereby not only restrained from being stimulated by the bisoprolol, but also the risk of a side effect such as bradycardia and vertigo to be caused due to excessive depression is eliminated to secure sufficient safety.
    • 要解决的问题:提供一种经皮给药装置,特别是在应用时,特别是重新施用时,能够施用一定量的比索洛尔,有效治疗或预防生物体的皮肤刺激。解决方案:经皮给药装置10 对比索洛尔包括支撑体1和层叠在支撑体1的一个表面上的压敏粘合剂层2,并且比索洛尔包含在压敏粘合剂层2中,比索洛尔释放速度的最大值为30μg/ cm 3 /小时以下,在从施用到皮肤上直到24小时后的时间段内,比索洛尔释放速度在从施加到皮肤上起算之后的时间内为10μg/ cm 3 /小时以下 皮肤长达24小时。 因此,皮肤不仅可以抑制比索洛尔的刺激,而且消除由于过度抑郁引起的副作用(如心动过缓和眩晕)的风险,以确保足够的安全性。
    • 3. 发明专利
    • Adhesive preparation containing bisoprolol
    • 包含双酚的胶体制剂
    • JP2012158612A
    • 2012-08-23
    • JP2012120476
    • 2012-05-28
    • Nitto Denko CorpToa Eiyo Ltdトーアエイヨー株式会社日東電工株式会社
    • IWAO YOSHIHIROOKUBO KATSUYUKIOKADA KATSUHIROMINAMI KUNIHIROYUASA SHUICHIRO
    • A61K31/138A61K9/70A61K47/10A61K47/14A61K47/32A61P9/06A61P9/10A61P9/12
    • PROBLEM TO BE SOLVED: To provide an adhesive preparation which has a low irritation to the skin surface, is superior in stability of bisoprolol in the preparation and further is capable of continuously administrating an effective amount of bisoprolol for treatment or prevention to the living body.SOLUTION: The adhesive preparation 10 has a support 1 and an adhesive layer 2 which is layered on one surface of the support 1. The adhesive layer 2 is characterized by containing bisoprolol, polyisobutylene, a tackifier and an organic liquid component which is compatible with polyisobutylene and tackifiers. Thus, the adhesive preparation having good skin adhesiveness, low skin irritation and reduced pain or adhesive residue at the time of removal from the skin surface can be provided. Further, the adhesive preparation in which the stability of bisoprolol in the adhesive preparation is excellent and an effective amount of bisoprolol for treatment and prevention can be continuously administrated to the living body through the skin surface is provided.
    • 要解决的问题:为了提供对皮肤表面具有低刺激性的粘合剂,在制剂中比基索洛尔的稳定性优异,并且还能够连续施用有效量的比索洛尔用于治疗或预防 活体。 粘合剂制剂10具有层叠在载体1的一个表面上的载体1和粘合剂层2.粘合剂层2的特征在于含有比索洛尔,聚异丁烯,增粘剂和有机液体组分,其为 与聚异丁烯和增粘剂相容。 因此,可以提供在从皮肤表面去除时具有良好的皮肤粘附性,低皮肤刺激性和减轻的疼痛或粘合剂残留的粘合剂。 此外,提供了粘贴剂中比索洛尔的稳定性优异的粘合剂制剂和用于治疗和预防的有效量的比索洛尔可以通过皮肤表面连续施用于生物体。 版权所有(C)2012,JPO&INPIT